Philadelphia, PA, February 4, 2014 - From birth, infants naturally show a preference for human contact and interaction, including faces and voices. These basic predispositions to social stimuli are altered in individuals diagnosed with autism spectrum disorders (ASD).
A new study published in Biological Psychiatry this week, from researchers at the Yale University School of Medicine, now reports that 6-month-old infants later diagnosed with autism divert their gaze from facial features when that face is speaking.
One of the best methods to examine autism in very young infants is the use of eye-tracking. This technology uses advanced video monitoring and special software that tracks and 'maps' exactly where the eyes were focused and for how long.
Dr. Frederick Shic and his colleagues used this method to examine how 6-month-old infants looked at videos of still, smiling, and speaking faces. The infants were later assessed at 3 years of age and divided into groups based on based on their diagnosis of ASD, other developmental delays, or typical development.
Infants who later developed ASD not only looked at all faces less than other infants, but also, when shown a face that was speaking, looked away from key facial features such as the eyes and mouth.
"These results suggest that the presence of speech disrupts typical attentional processing of faces in those infants later diagnosed with ASD," said Shic. "This is the first study to isolate an atypical response to speech as a specific characteristic in the first half year after birth that is associated with later emerging ASD."
These findings indicate that infants who later develop ASD have difficulty maintaining attention to relevant social information as early as 6 months of age, a phenomenon that could reduce the quality of their social and communicative exchanges with others and, consequently, the trajectory of their social development.
Autism typically can't be diagnosed until at least two years of age, but this and other studies confirm that abnormalities in behavior and attention can be detected as early as 6 months of age.
"It seems clear that brain changes related to autism appear much earlier than we traditionally diagnose this disorder," commented Dr. John Krystal, Editor of Biological Psychiatry. "This study elegantly illustrates that autism-related disturbances in social relatedness are present very early in life, shaping one's most fundamental social contacts."
These affected infants may be experiencing an altered social experience at a critical developmental point. The hope is that this and further research can help clarify how and when the developmental trajectory is altered in children who develop autism and, potentially, develop targeted interventions that could normalize their developmental processes.
The article is "Speech Disturbs Face Scanning in 6-Month-Old Infants Who Develop Autism Spectrum Disorder" by Frederick Shic, Suzanne Macari, and Katarzyna Chawarska (doi: 10.1016/j.biopsych.2013.07.009). The article appears in Biological Psychiatry, Volume 75, Issue 3 (February 1, 2014), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Dr. Frederick Shic at +1 203 764 5934 or firstname.lastname@example.org.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 135 Psychiatry titles and 13th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2012 Impact Factor score for Biological Psychiatry is 9.247.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 214 648 0880